Sermonix Pharma Issues Press Release Highlighting FDA Accepted Its Investigational New Drug Application For Ligand's Lasofoxifene; Will Begin Phase 2 Trial For Targeted Treatment of Women With ESR1 Mutations in Metastatic Breast Cancer